País: União Europeia
Língua: finlandês
Origem: EMA (European Medicines Agency)
Tanezumab
Pfizer Europe MA EEIG
N02
tanezumab
kipulääkkeet
Osteoarthritis; Pain
Treatment of moderate to severe chronic pain associated with osteoarthritis (OA) of the hip or knee in adult patients for whom treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and/or any opioid is ineffective, not tolerated or inappropriate.
Refused